FilingReader Intelligence

Pfizer launches 20-valent pneumococcal vaccine in India

August 11, 2025 at 07:03 PM UTC•By FilingReader AI

Pfizer launched its 20-valent Pneumococcal Polysaccharide Conjugate Vaccine for adults in India, effective August 11, 2025.

The single-dose vaccine targets 20 Streptococcus pneumoniae serotypes, providing enhanced protection against invasive and non-invasive pneumococcal disease.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

Primary Source Document

Pursuant to Regulation 30 of SEBI (LODR) Regulations 2015, we hereby inform that Company has announced the launch of its next generation 20-valent Pneumococcal Polysaccharide Conjugate ....August 11, 2025 at 01:36 PM UTC

Supplementary Source Documents

Pfizer Launches 20-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV20) for Adults in India, offering broad protection against Pneumococcal Disease.August 11, 2025 at 01:50 PM UTC

Pfizer

BSE:PFIZER•Bombay Stock Exchange

RSS feed for Pfizer

News Alerts

Get instant email alerts when Pfizer publishes news

Free account required • Unsubscribe anytime

Browse RSS Feeds

Filing Activity Timeline

View Complete Filing History →